RIZZO, FEDERICA
 Distribuzione geografica
Continente #
NA - Nord America 2.276
EU - Europa 2.151
AS - Asia 1.723
SA - Sud America 172
AF - Africa 51
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.390
Nazione #
US - Stati Uniti d'America 2.199
GB - Regno Unito 680
CN - Cina 629
SG - Singapore 595
IT - Italia 430
SE - Svezia 252
DE - Germania 251
HK - Hong Kong 180
BR - Brasile 144
RU - Federazione Russa 119
FI - Finlandia 74
IN - India 74
NL - Olanda 71
FR - Francia 70
CA - Canada 61
IE - Irlanda 55
VN - Vietnam 50
DK - Danimarca 44
KR - Corea 39
ID - Indonesia 36
CI - Costa d'Avorio 35
JP - Giappone 35
TR - Turchia 30
UA - Ucraina 26
AU - Australia 14
BE - Belgio 14
AR - Argentina 10
CH - Svizzera 10
IQ - Iraq 10
TW - Taiwan 9
AT - Austria 8
MX - Messico 8
BD - Bangladesh 7
ES - Italia 7
GR - Grecia 7
PL - Polonia 7
ZA - Sudafrica 6
PE - Perù 5
RO - Romania 5
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
SC - Seychelles 4
EC - Ecuador 3
EE - Estonia 3
EU - Europa 3
IR - Iran 3
LT - Lituania 3
MA - Marocco 3
MY - Malesia 3
NO - Norvegia 3
PY - Paraguay 3
UZ - Uzbekistan 3
BO - Bolivia 2
CL - Cile 2
DO - Repubblica Dominicana 2
HN - Honduras 2
HR - Croazia 2
KZ - Kazakistan 2
LK - Sri Lanka 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PH - Filippine 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
CO - Colombia 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
IL - Israele 1
KE - Kenya 1
KW - Kuwait 1
LB - Libano 1
NI - Nicaragua 1
OM - Oman 1
PR - Porto Rico 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
Totale 6.393
Città #
Southend 617
Singapore 353
Ashburn 335
Chandler 195
Milan 195
Hong Kong 175
Houston 171
Fairfield 147
Dallas 114
Beijing 112
Wilmington 104
Seattle 84
Ann Arbor 77
Woodbridge 68
Council Bluffs 61
Princeton 58
Dublin 51
Cambridge 44
Toronto 43
Hefei 42
Helsinki 42
Los Angeles 37
Santa Clara 37
Abidjan 35
Phoenix 32
Munich 31
Bengaluru 30
Jakarta 30
Shanghai 30
The Dalles 25
Buffalo 24
Guangzhou 24
Dearborn 23
Frankfurt am Main 23
Nanjing 23
San Jose 23
Boardman 22
Des Moines 22
Columbus 20
Cangzhou 19
Hanover 18
São Paulo 17
Mountain View 16
Hangzhou 15
Istanbul 15
Seoul 15
Ho Chi Minh City 14
Moscow 14
New York 14
Redmond 13
Rome 13
Grafing 12
Nanchang 12
Shenyang 12
Tokyo 12
Redwood City 11
Brussels 10
Changsha 10
Fuzhou 10
Jinan 10
Nuremberg 10
Mumbai 9
Tianjin 9
Orem 8
Ottawa 8
Shenzhen 8
Stockholm 8
Turku 8
Zhengzhou 8
Andover 7
Berlin 7
Castelnuovo del Garda 7
Chengdu 7
Falls Church 7
Jiaxing 7
Rho 7
Silver Spring 7
Taipei 7
Baghdad 6
Bitonto 6
Düsseldorf 6
Hanoi 6
Hebei 6
London 6
Roxbury 6
Boston 5
Brasília 5
Bridge 5
Chennai 5
Denver 5
Dong Ket 5
Kawaguchi 5
Manchester 5
Medford 5
Ningbo 5
Philadelphia 5
Piscataway 5
San Diego 5
Tappahannock 5
Torino 5
Totale 4.117
Nome #
Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model 391
Key role of SMN/SYNCRIP and RNA-Motif 7 in spinal muscular atrophy: RNA-Seq and motif analysis of human motor neurons 372
GENERAZIONE DI IPSC COME MODELLO IN VITRO E SVILUPPO DI UN POSSIBILE APPROCCIO TERAPEUTICO PER LA MALATTIA DI CHARCHOT-MARIE-TOOTH DI TIPO 2A(CMT2A) 368
Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches 341
Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model 305
Neural stem cell transplantation for neurodegenerative diseases 271
IPSC-derived neural stem cells act via kinase inhibition to exert neuroprotective effects in spinal muscular atrophy with respiratory distress type 1 267
Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype 245
Downregulation of glutamic acid decarboxylase in Drosophila TDP- 43-null brains provokes paralysis by affecting the organization of the neuromuscular synapses 223
Animal Models of CMT2A: State-of-art and Therapeutic Implications 217
Disease Modeling and Therapeutic Strategies in CMT2A: State of the Art 196
Genome-wide RNA-seq and proteomic analysis of motor neurons indicates selective cytoskeletal perturbation in Brown-Vialetto disease, partially rescued by riboflavin 188
Synaptotagmin 13 is neuroprotective across motor neuron diseases 187
Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model 184
Direct reprogramming of human astrocytes into neural stem cells and neurons 183
Morpholino antisense oligomer against SOD1 for amyotrophic lateral sclerosis therapy 176
Peptide-conjugated Morpholino Oligomers for treatment of Spinal Muscular Atrophy 174
Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy 170
A model for motor neuron degeneration and treatment of Spinal Muscular Atrophy using human induced pluripotent stem cells 156
Generation of skeletal muscle cells from embryonic and induced pluripotent stem cells as an in vitro model and for therapy of muscular dystrophies 154
Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis 153
Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis 151
Genetic correction of spinal muscular atrophy-induced pluripotent stem cells and motoneurons as a disease model and cell source for transplantation 146
MFN2-related neuropathies: clinical features, molecular pathogenesis and therapeutic perspectives 144
Mitochondrial fusion proteins and human diseases 141
Targeted gene correction of spinal muscular atrophy induced pluripotent stem cells and motoneurons as cell source for therapy 140
Selective mitochondrial depletion, apoptosis resistance, and increased mitophagy in human Charcot-Marie-Tooth 2A motor neurons 138
Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy δ7 mouse model phenotype 135
Clinical and genetic features of a cohort of patients with MFN2-related neuropathy 128
Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives 126
Stathmins and Motor Neuron Diseases: Pathophysiology and Therapeutic Targets 125
Charcot-Marie-Tooth type 2A in vivo models: Current updates 103
Development of a therapeutic approach for Spinal Muscular Atrophy with Respiratory Distress (SMARD1) using human induced pluripotent stem cell-derived neural stem cells and motor neurons 99
Targeting STMN2 for neuroprotection and neuromuscular recovery in Spinal Muscular Atrophy: evidence from in vitro and in vivo SMA models 95
Investigating the prevalence of MFN2 mutations in amyotrophic lateral sclerosis: insights from an Italian cohort 76
Advances and challenges in modeling Charcot-Marie-Tooth type 2A using iPSC-derived models 9
null 4
null 3
null 3
null 3
null 3
null 3
null 3
null 3
null 3
Totale 6.705
Categoria #
all - tutte 17.963
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.963


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021390 0 0 0 0 0 46 80 42 54 43 49 76
2021/2022664 27 57 40 90 36 65 35 26 86 74 33 95
2022/2023637 92 95 51 63 61 94 38 26 82 9 16 10
2023/2024417 14 32 19 40 95 24 18 23 47 12 29 64
2024/20251.219 65 109 53 122 79 50 40 97 56 128 160 260
2025/20261.314 268 182 283 204 195 182 0 0 0 0 0 0
Totale 6.705